Ashfield UK makes two new business development appointments for its growing team
October 16, 2015Medical Communications Ashfield UK
Ashfield has appointed David Tweedale and Ian Robinson as Business Development Managers to the UK Commercial and Clinical business, located …
The Prime Medical Group expands senior team in New York City
October 16, 2015Medical Communications
The Prime Medical Group is pleased to announce several key appointments to its New York office as the company continues …
Health apps now more popular than ever in the UK
October 16, 2015Medical Communications apps, digital pharma, health technology, technology
The use of health apps has considerably increased over the past years, according to a new survey that has found …
NICE requests more evidence on Duchenne muscular dystrophy therapy
October 16, 2015Medical Communications, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PCT Therapeutics, Translarna, ataluren
NICE has chosen not to recommend has PTC Therapeutics’ treatment Translarna for Duchenne muscular dystrophy (DMD), asking for further clarification …
The Prime Medical Group expands senior team in New York City
October 15, 2015Medical Communications The Prime Medical Group
The Prime Medical Group is pleased to announce several key appointments to its New York office as the company continues …
Valeant receives court writ over US drug pricing
October 15, 2015Medical Communications, Sales and Marketing Drug pricing, Isuprel, Nitropress, US, Valeant, subpoena
Valeant Pharmaceuticals has disclosed that it has received two subpoenas in the US, demanding evidence concerning the pricing and distribution …
$350m collaboration deal for BMS and Five Prime Therapeutics
October 15, 2015Research and Development BMS, Bristol-Myers Squibb, R&D, five prime, immuno-oncology, tumours
Bristol-Myers Squibb has signed a collaboration agreement with the US biotech firm Five Prime Therapeutics, for a Colony Stimulating Factor …
Ablynx and Merck begin immuno-oncology collaboration
October 15, 2015Research and Development Ablynx, Merck, immuno-oncology, nanobody, proof of concept
Ablynx has achieved a pre-clinical proof-of-concept with a nanobody construct as part of its immuno-oncology collaboration with Merck – triggering …
Allergan axes 117 jobs in Kythera buyout
October 15, 2015Allergan, Kythera
According to a notice filed with the state of California, Allergan will be laying off 117 employees at Kythera’s Westlake …
ABPI hits back at Prime Minister’s criticism of high drug prices
October 15, 2015Sales and Marketing ABPI, Drug pricing, Duchenne Muscular Dystrophy, NICE, Translarna, ataluren, david cameron, prime minister, rare disease
The ABPI has responded to comments made by UK Prime Minister David Cameron during yesterday’s Prime Minster’s Questions, in which …
Crescendo Biologics appoints Dr Peter Pack as chief exec
October 15, 2015Business Services, Research and Development
Crescendo Biologics has announced the appointment of Dr Peter Pack as chief executive, who will oversee the company’s new drug …
Novartis and Biogen launch drug access programmes in developing countries
October 15, 2015Manufacturing and Production, Sales and Marketing Biogen, Novartis, access, aid, corporate social responsibility, csr, humanitarian aid
Novartis and Biogen have begun new campaigns aimed at increasing access to medicines in developing countries. The Swiss firm has …
Merck and Incyte to initiate Keytruda, epacadostat combo trial
October 15, 2015Research and Development Incyte, Merck, R&D, melanoma, phase III, skin cancer
Merck and biopharma firm Incyte are to expand their clinical collaboration to include a Phase III study evaluating the combination …
Hilary Clinton’s pharma ‘enemies’ amongst her biggest financial supporters
October 14, 2015Drug pricing, Hilary Clinton, US, pricing reform
Hilary Clinton’s plans to make waging war with pharma companies a central plank of her US presidential campaign have been …
Turing faces antitrust probe over Daraprim price hike
October 14, 2015Sales and Marketing Daraprim, Turing Pharmaceuticals, turing
Turing Pharmaceuticals, the drug company that increased the price of the generic drug Daraprim 50-fold overnight, is facing an antitrust …
Johnson & Johnson begins Ebola vaccine trial in Sierra Leone
October 14, 2015Research and Development Ebola vaccine, Johnson & Johnson
Johnson & Johnson has begun a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen …
AstraZeneca accused of tax avoidance in Dutch scheme
October 14, 2015AstraZeneca, finance, tax, tax avoidance
AstraZeneca is the latest international firm to be accused of corporation tax avoidance, after an investigation claimed the firm is …
Novo chief executive ranked ‘world’s best’
October 14, 2015Medical Communications, Sales and Marketing Harvard Business Review, Lars Rebien Sorensen, Novo Nordisk
Novo Nordisk chief executive Lars Rebien Sørensen has been named the best-performing in the world by the Harvard Business Review. …
Mayor of London announces Takeda, UCL R&D partnership
October 14, 2015Research and Development London, R&D, Takeda, UCL, neurology
Takeda is teaming up with researchers at University College London (UCL) to identify and validate novel target genes for the …
Lisa Rae Schopf and Erik J. Spek bolster Vedanta Biosciences team
October 14, 2015Medical Communications, Research and Development
Vedanta Biosciences, a PureTech Health company developing a new class of therapies designed to modulate the human microbiome, has announced …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
